Braeburn Pharmaceuticals

Braeburn Pharmaceuticals is a pharmaceutical company operating in the field of addiction medicine, with a focus on treatments for opioid use disorder. The listing here corresponds to a Braeburn-associated location at 5028 Spruce Ln in Mohnton, Pennsylvania, in Berks County, just south of Reading. The company can be reached at (717) 364-7088, and additional corporate information is available through its website at braeburnrx.com.

Unlike a retail pharmacy or a clinic, Braeburn is a specialty pharmaceutical developer and commercial organization. Its work centers on bringing long-acting medications to market, supporting the clinicians and treatment programs that administer them, and maintaining the regulatory and distribution systems that controlled-substance therapies require. Much of the company's day-to-day activity involves medical affairs, field-based clinical education, market access, and regulatory compliance rather than direct patient-facing retail services.

Company Background

Braeburn was established in the early 2010s with backing from the life sciences investment firm Apple Tree Partners, which built the company around a specific thesis: that people receiving treatment for opioid use disorder would benefit from medications that do not require daily self-administration. Daily dosing regimens can create practical barriers, including the need for frequent clinic visits, and can also raise concerns about medication diversion and misuse. Long-acting formulations were seen as one way to address both issues at once.

The company has maintained its corporate base in Pennsylvania, with offices in the Philadelphia region, and has also had a presence in New Jersey during earlier phases of its history. Pennsylvania has been a logical home for the organization for two reasons. The state sits within one of the densest pharmaceutical corridors in the United States, giving the company access to experienced regulatory, clinical, and commercial talent. It has also been among the states most affected by the opioid crisis, which has made local treatment networks, provider groups, and public health agencies central to the company's work.

Therapeutic Focus

Braeburn's product development has concentrated on buprenorphine, a partial opioid agonist that is one of the medications recognized by federal health agencies as a standard of care for opioid use disorder. Buprenorphine reduces withdrawal symptoms and cravings while carrying a lower overdose risk profile than full agonists. Traditionally it has been taken daily as a sublingual film or tablet.

The company's approach has been to reformulate this established medication into delivery systems that last longer. Its portfolio has included work on implantable and injectable formats, each designed to maintain steady medication levels over extended periods. An earlier product in the company's history was a six-month buprenorphine implant, which Braeburn commercialized in the United States under an agreement with the product's original developer.

The company's principal current product is Brixadi, an extended-release buprenorphine injection administered under the skin. Brixadi received approval from the U.S. Food and Drug Administration in May 2023 for the treatment of moderate to severe opioid use disorder and became commercially available in the United States later that year. The product is offered in both weekly and monthly dosing options, which gives prescribers flexibility to match the treatment schedule to a patient's stage of recovery and individual circumstances. The underlying drug delivery technology was developed by the Swedish pharmaceutical company Camurus, and Braeburn holds commercialization rights for the United States market.

How the Product Reaches Patients

Because Brixadi is a controlled substance delivered by injection, it is distributed under a Risk Evaluation and Mitigation Strategy, commonly known as a REMS program. In practical terms, this means the medication is not picked up at a neighborhood pharmacy counter and self-administered. Instead, it is dispensed to certified healthcare settings, where a trained clinician performs the injection. Settings that commonly participate include:

• Opioid treatment programs and methadone clinics
• Office-based addiction treatment practices
• Hospital emergency departments and inpatient units
• Community health centers and federally qualified health centers
• Correctional health systems and reentry programs
• Behavioral health organizations offering integrated medical care

Patients interested in this type of treatment generally begin by speaking with a physician, physician assistant, or nurse practitioner who is authorized to prescribe buprenorphine. The clinician determines whether a long-acting injectable is clinically appropriate and, if so, arranges for administration at a participating site.

Distinguishing Characteristics

Several features set Braeburn apart within the broader pharmaceutical landscape. The first is the narrowness of its focus. Rather than maintaining a diversified portfolio across multiple therapeutic areas, the company has concentrated almost entirely on substance use disorder, which has shaped its clinical research priorities, its field team structure, and its relationships with public health stakeholders.

The second is its emphasis on flexible dosing. Offering both weekly and monthly injection schedules is unusual in this category and reflects an understanding that treatment needs change over time. Patients early in recovery may benefit from more frequent contact with a care team, while those who have stabilized may prefer fewer appointments.

The third is the company's engagement with treatment settings that are often underserved by pharmaceutical commercial teams, including correctional facilities, emergency departments, and safety-net providers. These environments present logistical and reimbursement challenges that require dedicated market access work.

Location and Service Area

The Mohnton address places this listing in southern Berks County, within the greater Reading area and roughly an hour from both Lancaster and the western Philadelphia suburbs. Braeburn's commercial reach, however, is national. Its field teams, medical science liaisons, and account personnel work with healthcare providers across the United States, and its products are available through certified sites in all regions where prescribers have established care.

Practical Information

Individuals seeking treatment should note that a pharmaceutical company cannot prescribe medication, provide medical advice, or serve as a point of entry into care. The appropriate first step is contacting a licensed healthcare provider, a local treatment program, or a national helpline that can make referrals.

The phone number and website listed are most useful for the following purposes:

• Healthcare providers seeking product information, prescribing details, or REMS certification guidance
• Pharmacists and clinic administrators with distribution or ordering questions
• Patients or caregivers looking for patient support program and co-pay assistance information
• Reporting of adverse events or product quality concerns
• Media, partnership, and employment inquiries

Prescribing information, safety details, and support program materials are posted on the company website, which is generally the fastest route to current documentation.